BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab; Capecitabine
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms BACCI
- 16 Oct 2017 Planned End Date changed from 1 Nov 2025 to 30 Jun 2021.
- 16 Oct 2017 Planned primary completion date changed from 1 Nov 2020 to 30 Nov 2020.
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.